Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 20 May 1988:
Vol. 240. no. 4855, pp. 1024 - 1026
DOI: 10.1126/science.2897133
Prev | Table of Contents | Next

Articles

Science, Vol 240, Issue 4855, 1024-1026
Copyright © 1988 by American Association for the Advancement of Science

articles

Radioimmunotherapy with alpha-particle-emitting immunoconjugates

RM Macklis, BM Kinsey, AI Kassis, JL Ferrara, RW Atcher, JJ Hines, CN Coleman, SJ Adelstein, and SJ Burakoff

Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02115.

Alpha particles are energetic short-range ions whose higher linear energy transfer produces extreme cytotoxicity. An alpha-particle-emitting radioimmunoconjugate consisting of a bismuth-212-labeled monoclonal immunoglobulin M specific for the murine T cell/neuroectodermal surface antigen Thy 1.2 was prepared. Analysis in vitro showed that the radioimmunoconjugate was selectively cytotoxic to a Thy 1.2+ EL-4 murine tumor cell line. Approximately three bismuth-212-labeled immunoconjugates per target cell reduced the uptake of [3H]thymidine by the EL-4 target cells to background levels. Mice inoculated intraperitoneally with EL-4 cells were cured of their ascites after intraperitoneal injection of 150 microcuries of the antigen-specific radioimmunoconjugate, suggesting a possible role for such conjugates in intracavitary cancer therapy.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1.
M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, et al. (2007)
PNAS 104, 8444-8448
   Abstract »    Full Text »    PDF »
The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the {alpha}-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia.
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, S. Yu, H.-S. Kim, C. K. Goldman, C. H. Paik, et al. (2006)
Cancer Res. 66, 8227-8232
   Abstract »    Full Text »    PDF »
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.
Z. Zhang, M. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, B. Beck, C. Goldman, M. W. Brechbiel, and T. A. Waldmann (2006)
Blood 108, 1007-1012
   Abstract »    Full Text »    PDF »
Radiobiologic Principles in Radionuclide Therapy.
A. I. Kassis and S. J. Adelstein (2005)
J. Nucl. Med. 46, 4S-12S
   Abstract »    Full Text »    PDF »
The Promise of Targeted {alpha}-Particle Therapy.
D. A. Mulford, D. A. Scheinberg, and J. G. Jurcic (2005)
J. Nucl. Med. 46, 199S-204S
   Abstract »    Full Text »    PDF »
Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin.
E. Dadachova, J. D. Nosanchuk, L. Shi, A. D. Schweitzer, A. Frenkel, J. S. Nosanchuk, and A. Casadevall (2004)
PNAS 101, 14865-14870
   Abstract »    Full Text »    PDF »
Engineered Liposomes for Potential {alpha}-Particle Therapy of Metastatic Cancer.
S. Sofou, J. L. Thomas, H.-y. Lin, M. R. McDevitt, D. A. Scheinberg, and G. Sgouros (2004)
J. Nucl. Med. 45, 253-260
   Abstract »    Full Text »    PDF »
Selective T-cell ablation with bismuth-213-labeled anti-TCR{alpha}{beta} as nonmyeloablative conditioning for allogeneic canine marrow transplantation.
W. A. Bethge, D. S. Wilbur, R. Storb, D. K. Hamlin, E. B. Santos, M. W. Brechbiel, D. R. Fisher, and B. M. Sandmaier (2003)
Blood 101, 5068-5075
   Abstract »    Full Text »    PDF »
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.
M. Zhang, Z. Zhang, K. Garmestani, J. Schultz, D. B. Axworthy, C. K. Goldman, M. W. Brechbiel, J. A. Carrasquillo, and T. A. Waldmann (2003)
PNAS 100, 1891-1895
   Abstract »    Full Text »    PDF »
Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha -emitting radionuclide, bismuth 213.
M. Zhang, Z. Yao, K. Garmestani, D. B. Axworthy, Z. Zhang, R. W. Mallett, L. J. Theodore, C. K. Goldman, M. W. Brechbiel, J. A. Carrasquillo, et al. (2002)
Blood 100, 208-216
   Abstract »    Full Text »    PDF »
Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts.
B. M. Sandmaier, W. A. Bethge, D. S. Wilbur, D. K. Hamlin, E. B. Santos, M. W. Brechbiel, D. R. Fisher, and R. Storb (2002)
Blood 100, 318-326
   Abstract »    Full Text »    PDF »
Response of LNCaP Spheroids after Treatment with an {{alpha}}-Particle Emitter (213Bi)-labeled Anti-Prostate-specific Membrane Antigen Antibody (J591).
A. M. Ballangrud, W.-H. Yang, D. E. Charlton, M. R. McDevitt, K. A. Hamacher, K. S. Panageas, D. Ma, N. H. Bander, D. A. Scheinberg, and G. Sgouros (2001)
Cancer Res. 61, 2008-2014
   Abstract »    Full Text »
High-Linear Energy Transfer (LET) {{alpha}} versus Low-LET {beta} Emitters in Radioimmunotherapy of Solid Tumors: Therapeutic Efficacy and Dose-limiting Toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' Fragments in a Human Colonic Cancer Model.
T. M. Behr, M. Behe, M. G. Stabin, E. Wehrmann, C. Apostolidis, R. Molinet, F. Strutz, A. Fayyazi, E. Wieland, S. Gratz, et al. (1999)
Cancer Res. 59, 2635-2643
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)